Project Grant R21AR084708

Award Date 9/24/24
Completion Date 8/31/26
Dollars Obligated $367K
Federal Grant Program
93.846
Assistance Type
Project Grant
Place of Performance
Columbia, MO 65211, USA
Similar Awards
This Project Grant award of $139,895.00 from the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846) will support research into the link between inflammatory arthritis and the development of cardiovascular disease. The key objectives are to investigate whether "trained immunity" - the phenomenon where innate immune cells become reprogrammed to respond more efficiently to a...
This federal Project Grant award from the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846), provides $735,372.00 to Brigham & Women's Hospital Inc. to conduct research on T cell expression of inflammatory chemokine receptors in chronic autoimmune conditions. The research aims to identify transcription factors and cytokines that regulate the expression of key chemokine...
This federal Project Grant award, valued at $715,957 and awarded by the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) under CFDA Program 93.846 - Arthritis, Musculoskeletal and Skin Diseases Research, supports research to elucidate the molecular mechanisms by which interferon cytokines promote the differentiation and expansion of T peripheral helper (Tph) cells in systemic lupus erythematosus (SLE) patients. The award, with a project period from March 2025 to...
This federal Project Grant award, funded by the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), aims to develop a novel therapeutic approach to improve angiogenesis and wound healing by delivering apoptotic neutrophils within a degradable hydrogel scaffold. The $172,700 award, effective August 20, 2024 through July 31, 2026, supports research to investigate the effects of the hydrogel-apoptotic neutrophil delivery on macrophage angiogenic signaling and its impact...
This federal Project Grant award from the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846), provides $242,310 to Rockefeller University to investigate the long-term systemic consequences of type 2 skin inflammation on epithelial stem cells. The research aims to uncover how allergic type 2 inflammation impacts the functional responsiveness and epigenetic state of epithelial stem...
This federal Project Grant award from the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846), provides $664,933 to Beth Israel Deaconess Medical Center, Inc. (BIDMC) to investigate cellular and molecular mechanisms of IL-17A in the pathogenesis of psoriatic arthritis. The research aims to develop a novel animal model to define the early cellular and molecular pathways that drive...
The National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) awarded a $220,224 Project Grant (CFDA 93.846 - Arthritis, Musculoskeletal and Skin Diseases Research) to The Regents of the University of Colorado, operating as the University of Colorado, with a period of performance from July 4, 2024 to August 31, 2027. The funding will support the development of granular hydrogels for the controlled delivery of immunomodulatory and angiogenic extracellular vesicles to enhance...
This Project Grant award from the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846), provides $383,570 to Temple University to conduct research on interleukin-36 (IL-36) cytokine activation and inactivation mechanisms. The project aims to improve understanding of IL-36 functions and their role in inflammatory conditions, such as atopic dermatitis, psoriasis, and skin infections,...
This federal Project Grant award from the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846), will provide $196,460 to the University of Pittsburgh to test a novel microphysiological system as a tool to study neuroimmune interactions in osteoarthritis pain. The goal is to use this system, which includes cartilage, synovial-like, and innervated tissue, to investigate the influence...
This $375,100 federal Project Grant award was provided by the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846). The grant funds a study to investigate the interplay between nucleic-acid-dependent phase separation and immune responses against cyclic GMP-AMP synthase (cGAS) in systemic lupus erythematosus (SLE). The research aims to determine how changes in the biophysical...

This Project Grant award, funded by the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846), supports research to investigate the role of reverse transendothelial migration of neutrophils in inflammation resolution. The $366,797 award, with a project period from Sep 24, 2024 to Aug 31, 2026, aims to provide new insights into the mechanisms by which certain inflammatory mediators, such as LTB4, PGE2, and LXA4, can impact the process of neutrophils re-entering the vasculature after entering inflamed tissues. This research seeks to enhance the understanding of how inflammation resolution occurs and may inform the development of novel therapeutic approaches for chronic inflammatory diseases like arthritis.

Generated 7/1/25, 2:03 AM